In >230,000 individuals from the Helix Research Network, Lynch syndrome cancer risk varied substantially by gene @JCOOA_ASCO@kellyschiabor
MLH1/MSH2 showed the highest colorectal cancer risk, while PMS2 demonstrated markedly lower penetrance & later onset
https://t.co/AGPsIvQehH
Todo lo que sabemos hoy sobre el cáncer de mama: diagnóstico, tratamientos y factores de riesgo https://t.co/09A8HqPg1T via @uestudio_es@quironsalud@telva@elmundoes
Just started👉2025 United States #ProstateCancer Consensus Conference (USPCCC) 👉with @AlanBryce9 ‘s introductory remarks. @philkuo@cityofhope debating for PSMA PET for treatment selection. Caveat👉 Medical conditions with false positive PSMA PET lesions 👇@urotoday@PCFnews
Socioeconomic inequities in prostate cancer care: private versus public treatment settings pose a significant impact on overall survival https://t.co/790ByVThsC
influence of drug access on #overalsurvival#prostatecancer@lucianaholtz@StenioZequi
Huge congrats to #NizarTannirMD@MDAndersonNews who drove forward this impt trial (#PIVOT09) comparing pegylated #IL2/#nivolumab to #TKI; was a privelege to work w him & others (@nirvanaformiga@neerajaiims@Daniel_J_George) on this trial now in @JCO_ASCO. PFS & OS no different; RR a bit lower in experimental arm. We saw @brian_rini & @DrChoueiri present genomic data from #KN426 & #CLEAR at #ASCO24 & prev saw genomic data from #CM214 presented by @motzermd. Wish we had the opportunity to look at that here - given modest activity w #bempeg, could offer insights on which pts could get IO monotx - something we discuss often after #KN427 but do infrequently in practice.